Guggenheim reiterates Buy rating for Zura Bio stock

Published on 10/05/2026 at 02:04 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Guggenheim's Buy rating puts Zura Bio stock at a USD 20.00 target. Second-quarter loss reached USD 26.30 million.

ZURA, KYG9TY5A1016, Illustration mit AI erstellt.

Zura Bio Limited (ISIN KYG9TY5A1016) received a reiterated Buy rating and a USD 20.00 price target from Guggenheim in a report dated October 2, 2026, according to Markets Insider. The recommendation keeps the analyst debate centered on Zura Bio's clinical pipeline while the company remains loss-making.

Analysts set a wide target spread

Leerink Partners also reiterated a Buy rating on October 2, 2026, but assigned a USD 11.00 price target, according to Markets Insider. The two targets differ by USD 9.00, making valuation assumptions a central issue for the stock rather than a single, uniform analyst view.

A separate MarketBeat report cited Guggenheim's earlier increase from USD 15.00 to USD 20.00 and Wedbush's increase from USD 15.00 to USD 22.00, both dated August 12, 2026. Those figures provide a concrete reference for the current targets, but they also show how sharply research assumptions differ.

Second-quarter loss tests the pipeline story

Zura Bio reported a GAAP net loss of USD 26.30 million for the quarter ended June 30, 2026, compared with USD 15.99 million in the prior-year quarter, according to Markets Insider. The larger loss places the USD 20.00 target firmly in the category of a development-stage valuation that depends on future clinical progress.

The investor-relations page says Zura Bio is evaluating tibulizumab in two Phase 2 studies, TibuSHIELD for hidradenitis suppurativa and TibuSURE for systemic sclerosis. It also says a third study, NEXUS-PMR, is planned to begin by year-end 2026, according to Zura Bio. That schedule gives the target debate a measurable operational marker: the expansion of the Phase 2 program.

Nasdaq value stays below analyst targets

On the Nasdaq, ZURA was last at USD 4.11 on October 2, 2026 at 4:00 p.m. ET, down 0.72 percent from USD 4.14. Its market capitalization was USD 390.4 million, while the 52-week range stood at USD 3.15 to USD 7.44.

The market data put Guggenheim's USD 20.00 target USD 15.89 above the last Nasdaq price and Leerink's USD 11.00 target USD 6.89 higher. Zura Bio therefore remains a clinical-stage biotechnology valuation story, with analyst targets tied to trial execution and the company's cash-funded development plans.